AKT1 and renal carcinoma: The hsa‐miR‐205‐5p enhances the chemosensitivity of renal carcinoma cells to 5‐FU and oxaliplatin by targeting Vascular Endothelial Growth Factor A (VEGFA) and modulating the PI3K/Akt signaling pathway (Huang et al. 2019).